|
NR 1-3/2007
|
|
|
|
|
|
|
|
|
VEGF a zwyrodnienie
plamki związane z wiekiem.
Część II. Inhibitory VEGF w leczeniu zwyrodnienia plamki
związanego z wiekiem
VEGF in age-related macular
degeneration.
Part II. VEGF inhibitors use in age-related macular degeneration
treatment
Edward Wylęgała1,2, Sławomir
Jan Teper2
1 Z Zakładu Pielęgniarstwa i Społecznych Problemów
Medycznych Śląskiej Akademii Medycznej w Katowicach
Kierownik: dr hab. n. med. Edward Wylęgała
2 Z Oddziału Okulistycznego Okręgowego Szpitala
Kolejowego w Katowicach
Ordynator: dr hab. n. med. Edward Wylęgała |
|
|
| Summary: |
Wet AMD remains a
therapeutic challenge. VEGF inhibitors are new promising
group of medical agents undergoing advanced clinical
trials. Oncology is the main specialty using anti-VEGF
therapy. Two agents were designed from the beginning as
ophthalmologic medicines. These are pegaptanib and
ranibizumab. In the paper there is mechanism, efficacy
and safety data presented, especially coming from
multi-center randomized clinical trials. Monoclonal
VEGF-antibodies (ranibizumab and bevacizumab) seem to be
most effective in wet AMD treatment. Because of
important physiological VEGF role long-term observation
is needed to confirm safety of VEGF inhibition. |
| Słowa kluczowe: |
VEGF, AMD, inhibitory VEGF. |
| Key words: |
VEGF, AMD, VEGF
inhibitors. |
|
|
|
|
|
|
